has been refreshed! Take a tour.
Issue Number 13                                         July 30, 1998


1. New DTaP vaccine licensed by FDA

July 29, 1998

On July 29, 1998, FDA approved a product license application (PLA) for Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP). The trade name of this vaccine is Certiva. The vaccine is indicated for the active immunization of persons 6 weeks to 7 years of age (prior to the seventh birthday).

Certiva was evaluated in a randomized, double-blind placebo controlled NICHD sponsored trial conducted in Sweden.*  Certiva contains one pertussis antigen-inactivated pertussis toxin (PT).

Manufacturing of Certiva: The D and T bulk concentrates for use in further manufacturing are produced by Statens Seruminstitut, Copenhagen, Denmark. The aP antigen is manufactured by North American Vaccine, Inc., of Beltsville, Maryland. DTaP is formulated at the Beltsville facility, and is filled and labeled at Abbott Laboratories in McPherson, Kansas.

Please see the package insert for additional information.

*Trollfors B, et al.: A placebo-controlled trial of a pertussis-toxoid vaccine. N Engl J Med 1995 Oct 19;333(16):1045-50.

About IZ Express

IZ Express is supported in part by Grant No. 1NH23IP922654 from CDC’s National Center for Immunization and Respiratory Diseases. Its contents are solely the responsibility of and do not necessarily represent the official views of CDC.

IZ Express Disclaimer
ISSN 2771-8085

Editorial Information

  • Editor-in-Chief
    Kelly L. Moore, MD, MPH
  • Managing Editor
    John D. Grabenstein, RPh, PhD
  • Associate Editor
    Sharon G. Humiston, MD, MPH
  • Writer/Publication Coordinator
    Taryn Chapman, MS
    Courtnay Londo, MA
  • Style and Copy Editor
    Marian Deegan, JD
  • Web Edition Managers
    Arkady Shakhnovich
    Jermaine Royes
  • Contributing Writer
    Laurel H. Wood, MPA
  • Technical Reviewer
    Kayla Ohlde

This page was updated on .